EUVIMEDEUVIMED entdecken
Crossref

A Novel RORγ-Selective Agonist Facilitates the Infiltration of Effector T Cells and Innate Immune Cells into Tumor Tissue, Demonstrating Antitumor Efficacy

Tsuyoshi Terawaki, Akane Suzukawa, Minako Tanimoto, Shunichi Fukuda, Takayuki Yamaguchi

Biological and Pharmaceutical Bulletin · 2025

DOI: 10.1248/bpb.b25-00540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Tsuyoshi Terawaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Central Pharmaceutical Research Institute, Takatsuki Research Center, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Antineoplastic Agents, Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoic acid receptor-related orphan receptor gamma (RORγ) is a key transcriptional factor that plays a crucial role in the differentiation and activation of Type 17 cells, such as interleukin-17 (IL-17)-producing CD4+ T (Th17) cells and CD8+ T (Tc17) cells, which are known to boost antitumor responses. Although a RORγ agonist (LYC-55716) has been under clinical evaluation, the precise effects of RORγ agonists on immune cells within tumor environments remain unclear. In our study, we investigated the role of tumor-infiltrating immune cells in the MC38 syngeneic mouse model of colorectal cancer using Compound-34, a novel orally available RORγ-selective agonist we discovered. Our findings revealed that Compound-34 exerts its antitumor efficacy by modulating immune cell activity rather than directly targeting tumor cells. Specifically, Compound-34 increased the infiltration of effector T cells, including Th17 and Tc1 (interferon [IFN]-γ+ CD8+ T) cells, as well as innate immune cells like natural killer (NK) and natural killer T (NKT) cells, within the MC38 tumor tissue. Following the administration of Compound-34, there was an increase in IFNγ and Granzyme B within the MC38 tumor tissue, accompanied by an increase in the infiltration of cytotoxic immune cells. Moreover, the addition of Th17-derived cytokines to MC38 cells stimulated the release of CXCL10, a chemokine crucial for immune cell recruitment. These results offer valuable insights into the immunomodulatory and therapeutic potential of RORγ agonists in cancer immunotherapy, highlighting their role in enhancing immune cell infiltration and activity within tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 1, Group F, Member 3Antineoplastic AgentsColorectal NeoplasmsLymphocytes, Tumor-InfiltratingAnimalsMiceMice, Inbred C57BLImmunity, InnateCell Line, TumorCD8-Positive T-LymphocytesTh17 CellsInterferon-gammaFemaleKiller Cells, Natural

Stichwörter der Autor:innen

RORγ agonistT helper 17 cell (Th17)cancer immunotherapyeffector T cellinnate immune cellretinoic acid receptor-related orphan receptor gamma (RORγ)

Substanzen

Nuclear Receptor Subfamily 1, Group F, Member 3Antineoplastic AgentsInterferon-gammaRorc protein, mouse

Autor:innen und Institutionen

  • Central Pharmaceutical Research Institute, Takatsuki Research Center, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.

Zitieren

APA

Terawaki, T., Suzukawa, A., Tanimoto, M., Fukuda, S., & Yamaguchi, T. (2025). A Novel RORγ-Selective Agonist Facilitates the Infiltration of Effector T Cells and Innate Immune Cells into Tumor Tissue, Demonstrating Antitumor Efficacy. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00540

Vancouver

Terawaki T, Suzukawa A, Tanimoto M, Fukuda S, Yamaguchi T. A Novel RORγ-Selective Agonist Facilitates the Infiltration of Effector T Cells and Innate Immune Cells into Tumor Tissue, Demonstrating Antitumor Efficacy. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00540

BibTeX
@article{Terawaki2025,
  author = {Terawaki, Tsuyoshi and Suzukawa, Akane and Tanimoto, Minako and Fukuda, Shunichi and Yamaguchi, Takayuki},
  title = {A Novel RORγ-Selective Agonist Facilitates the Infiltration of Effector T Cells and Innate Immune Cells into Tumor Tissue, Demonstrating Antitumor Efficacy},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2025},
  doi = {10.1248/bpb.b25-00540}
}
Kostenlos starten →